Breaking News Instant updates and real-time market news.

ARGO

Argo Group

$63.82

2.54 (4.14%)

, LYV

Live Nation

$64.79

0.32 (0.50%)

10:16
11/12/19
11/12
10:16
11/12/19
10:16

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Argo Group (ARGO) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Christopher Campbell saying he believes the company's "sizable" Q4 International reserve charge will restore balance sheet confidence and that new CEO Kevin Rehnberg's U.S. Operations outperformance can be replicated in its International segment. 2. Live Nation (LYV) upgraded to Outperform from In Line at Evercore ISI with analyst David Joyce saying he believes Live Nation shares have "pulled back needlessly" following its Q3 earnings results, and recommended taking advantage of the pullback. 3. Rent-A-Center (RCII) upgraded to Buy from Hold at Stifel with analyst John Baugh saying the recent pullback in the shares creates an attractive entry point. 4. Crowdstrike (CRWD) upgraded to Neutral from Sell at Goldman Sachs with analyst Heather Bellini she sees a more balanced risk/reward with the stock down 23% since her October 11 downgrade to Sell. 5. Teva (TEVA) upgraded to Neutral from Underweight at JPMorgan with analyst Christopher Schott citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ARGO

Argo Group

$63.82

2.54 (4.14%)

LYV

Live Nation

$64.79

0.32 (0.50%)

RCII

Rent-A-Center

$23.13

0.78 (3.49%)

CRWD

Crowdstrike

$47.25

1.07 (2.32%)

TEVA

Teva

$9.40

0.07 (0.75%)

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

ARGO Argo Group
$63.82

2.54 (4.14%)

11/11/19
KBWI
11/11/19
UPGRADE
Target $74
KBWI
Outperform
Argo Group upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Christopher Campbell upgraded Argo Group to Outperform from Market Perform with a $74 price target. The analyst believes the company's "sizable" Q4 International reserve charge will restore balance sheet confidence and that new CEO Kevin Rehnberg's U.S. Operations outperformance can be replicated in its International segment. Further, he sees little investment impact from A.M. Best's negative outlook.
11/08/19
11/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Argo Group (ARGO) downgraded to Market Perform from Outperform at William Blair with analyst Adam Klauber citing a lower earnings outlook following the company's Q3 results. 2. RA Pharmaceuticals (RARX) was downgraded to Hold from Buy at Stifel and to Neutral from Buy at Guggenheim. 3. Newtek Business (NEWT) downgraded to Market Perform from Outperform at Raymond James with analyst Robert Dodd saying he believes the current valuation reflects a positive outlook, while loan growth indicators have declined. 4. Gap (GPS) downgraded to Market Perform from Outperform at Telsey Advisory. 5. Albemarle (ALB) downgraded to Underweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying Albemarle, currently trading at 11.2 times estimated EBITDA for 2020, is overvalued. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/07/19
WBLR
11/07/19
DOWNGRADE
WBLR
Market Perform
Argo Group downgraded to Market Perform from Outperform at William Blair
William Blair analyst Adam Klauber downgraded Argo Group to Market Perform from Outperform citing a lower earnings outlook following the company's Q3 results.
10/30/19
BOSC
10/30/19
DOWNGRADE
BOSC
Neutral
Argo Group downgraded to Neutral from Outperform at Boenning & Scattergood
Boenning & Scattergood downgraded Argo Group to Neutral from Outperform.
LYV Live Nation
$64.79

0.32 (0.50%)

11/11/19
11/11/19
UPGRADE
Target $73

Outperform
Live Nation upgraded to Outperform from In Line at Evercore ISI
As previously reported, Evercore ISI analyst David Joyce upgraded Live Nation to Outperform from In Line with a $73 price target. The analyst believes Live Nation shares have "pulled back needlessly" following its Q3 earnings results, and recommended taking advantage of the pullback. Joyce sees 2020 as another year of "strong, double-digit" growth in adjusted operating income, or AOI, seeing 2020 AOI of $1.1B. He added that "concert-going is a recession-resilient business model" and as such, he doesn't see any potential recession impact.
11/11/19
EVER
11/11/19
UPGRADE
Target $73
EVER
Outperform
Live Nation upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst David Joyce upgraded Live Nation Entertainment to Outperform from In Line with a $73 price target.
10/25/19
JEFF
10/25/19
NO CHANGE
Target $84
JEFF
Buy
Basement East booking positive for Live Nation shares, says Jefferies
Jefferies analyst Khoa Ngo says data work suggests Live Nation Entertainment serving as the exclusive booking agent of The Basement East venue should be additive over the long-term and positive for shares. While financial details were not disclosed, it is important to quantify the venue's popularity to assess the value capture opportunities, which "should be plenty," Ngo tells investors in a research note titled "Honky Tonk Value Capture." The analyst reiterates a Buy rating on Live Nation shares with an $84 price target.
10/08/19
MSCO
10/08/19
INITIATION
Target $75
MSCO
Equal Weight
Live Nation initiated with an Equal Weight rating at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne initiated coverage of Live Nation with an Equal Weight rating and $75 price target. While the company benefits from a leading position in the growing live events industry, consensus estimates call for double-digit adjusted operating income growth over the next four years and the stock's multiple has expanded by 40% in the last three years, leaving the stock as "a fairly consensus long priced for perfection," Swinburne tells investors.
RCII Rent-A-Center
$23.13

0.78 (3.49%)

11/12/19
STFL
11/12/19
UPGRADE
Target $28
STFL
Buy
Rent-A-Center upgraded to Buy from Hold at Stifel
Stifel analyst John Baugh upgraded Rent-A-Center to Buy from Hold with an unchanged price target of $28. The recent pullback in the shares creates an attractive entry point, Baugh tells investors in a research note. With the company's expense cuts now completed, its balance sheet in "good shape,"and a "significantly improved ability to tackle" the $25B-$30B lease-to-own total addressable market, Rent-A-Center shares represent solid value at current levels, contends the analyst.
06/24/19
06/24/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. United Technologies (UTX) upgraded to Outperform from Market Perform at Cowen with analyst Cai von Rumohr citing the selloff in the shares after the Raytheon (RTN) merger announcement. 2. Deere (DE) and Agco (AGCO) upgraded to Buy from Hold at Jefferies. 3. Rent-A-Center (RCII) upgraded to Equal Weight from Underweight at Stephens with analyst Vincent Caintic citing what he sees as "massive potential" for third-party retailer Rent-To-Own, telling investors that he wouldn't want to be short any Rent-To-Own stock he covers as a result. 4. Hostess Brands (TWNK) upgraded to Buy from Neutral at UBS with Steven Strycula citing three catalysts he sees. 5. Dunkin' Brands (DNKN) upgraded to Outperform from Neutral at Wedbush with analyst Nick Steyan saying he believes Dunkin' U.S. is currently undergoing an inflection in same-store sales growth that is underappreciated by the Street. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/19
08/08/19
UPGRADE
Target $32

Buy
Rent-A-Center upgraded to Buy at Janney Montgomery Scott after 'solid' results
As previously reported, Janney Montgomery Scott analyst John Rowan upgraded Rent-A-Center to Buy from Neutral after the company reported "solid" results. Citing both the company's "strong" quarter and some of the other repositioning items management has done, the analyst thinks Rent-A-Center is in a "strong position" going forward to drive EPS growth and capital returns to shareholders. Rowan also raised his price target on the shares to $32 from $29.
08/08/19
JANY
08/08/19
UPGRADE
JANY
Buy
Rent-A-Center upgraded to Buy from Neutral at Janney Montgomery Scott
CRWD Crowdstrike
$47.25

1.07 (2.32%)

11/12/19
GSCO
11/12/19
UPGRADE
Target $55
GSCO
Neutral
Crowdstrike upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Heather Bellini upgraded Crowdstrike Holdings to Neutral from Sell with a price target of $55, down from $66. The shares closed Monday down $1.01 to $46.20. The analyst, who continues to view CrowdStrike as a leading next-generation endpoint security vendor, sees a more balanced risk/reward with the stock down 23% since her October 11 downgrade to Sell.
10/23/19
NOMU
10/23/19
INITIATION
Target $65
NOMU
Buy
Nomura Instinet starts Crowdstrike with Buy rating, $65 price target
Nomura Instinet analyst Christopher Eberle initiated coverage of Crowdstrike with a Buy rating and $65 price target. The company is disrupting the endpoint security market with the introduction of its "modern, cloud-native security platform," Eberle tells investors in a research note. He believes "superior" proprietary technology, "rapid" customer adoption, and Crowdstrike's open architecture will continue to drive greater adoption both within security and beyond. As a result, the analyst expects the company's sales growth to continue to exceed expectations for "several years to come."
10/23/19
NOMU
10/23/19
INITIATION
Target $65
NOMU
Buy
Crowdstrike initiated with a Buy at Nomura Instinet
Nomura Instinet started Crowdstrike with a Buy rating and $65 price target.
10/15/19
NEED
10/15/19
NO CHANGE
Target $92
NEED
Buy
Crowdstrike should be bought on weakness amid correction, says Needham
Needham analyst Alex Henderson says that while the stock's correction may not be complete, he recommends buying shares of Crowdstrike "over time." The analyst reiterates a Buy rating on the name with a $92 price target. Crowdstrike's platform and efficacy are establishing one of the core platforms in security regardless of the strategy of the customer, Henderson tells investors in a research note. The analyst also sees a "surprisingly low risk environment" for CrowdStrike as "legacy players are falling away." Henderson, who calls Crowdstrike one of his favorite names, recommends investors buy the high-growth cloud security names following on weakness.
TEVA Teva
$9.40

0.07 (0.75%)

11/12/19
JPMS
11/12/19
UPGRADE
Target $8
JPMS
Neutral
JPMorgan upgrades Teva to Neutral on stabilizing fundamentals
JPMorgan analyst Christopher Schott upgraded Teva Pharmaceuticals to Neutral from Underweight with an unchanged price target of $8. The analyst, who remains "fairly bearish" on the company's longer term setup, cites valuation for the upgrade with the stock down 55% year-to-date. Further, Teva's near-to-mid-term fundamentals are stabilizing, unlike some of its peers, Schott tells investors in a research note. As such, the analyst sees a "decidedly less-negative" setup today than several months ago.
11/12/19
JPMS
11/12/19
UPGRADE
Target $8
JPMS
Neutral
Teva upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Christopher Schott upgraded Teva Pharmaceutical Industries to Neutral from Underweight with an $8 price target.
10/22/19
JEFF
10/22/19
NO CHANGE
Target $8
JEFF
Hold
Can Teva reach global settlement to avoid bankruptcy, Jefferies asks
Teva Pharmaceutical Industries reached an agreement yesterday with the two bellwether Ohio counties related to opioid litigation for $20M and $25M of generic Suboxone over three years, thereby avoiding a risky trial, Jefferies analyst David Steinberg tells investors in a research note. Next up is whether Teva can reach a global settlement and avoid bankruptcy, adds the analyst. Teva indicates there's an agreement in principle with four states, "which would likely remove this major overhang and provide clarity for investors," according to Steinberg. He calculates an additional accrual of ~$835M based on the proposed terms. If a global settlement of this nature can be formalized, the prospect of a bankruptcy for Teva would arguably be off the table, contends the analyst. Steinberg says the potential global settlement, assuming agreement from other key parties over the next few months, "looks to be balance sheet and cash flow friendly" and seemingly would not significantly add to Teva's upcoming near term debt maturities. He keeps a Hold rating on the shares with an $8 price target. The stock closed Monday at $8.15.
10/17/19
10/17/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Container Store (TCS) upgraded to Neutral from Sell at Goldman Sachs with analyst Kate McShane saying after the recent underperformance, the she sees less downside risk for Container Store shares. 2. Teva (TEVA) upgraded to Buy from Hold at Gabelli with analyst Kevin Kedra citing reports that the company had proposed to settle its opioid litigation by giving away $15B of free drugs. 3. Boston Beer (SAM) upgraded to Outperform from Market Perform at Cowen with analyst Vivien Azer saying with Truly continuing to drive "outsized growth," and with new formulations and a lemonade line-extension slated for next year, the brand will continue to transform Boston Beer's "growth algorithm" and offset continued softness in beer and cider. 4. Cirrus Logic (CRUS) upgraded to Equal Weight from Underweight at Barclays analyst Blayne Curtis saying he no longer sees a downside catalyst and risk to consensus estimates. 5. Autoliv (ALV) upgraded to In Line from Underperform at Evercore ISI with analyst Chris McNally citing seasonality, the company's upcoming Capital Markets Day and as he rolled forward his auto supplier targets to 2021. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:31
12/07/19
12/07
19:31
12/07/19
19:31
Hot Stocks
Magenta reports results from MGTA-145 stem cell mobilization program »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PFE

Pfizer

$38.29

0.26 (0.68%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:29
12/07/19
12/07
19:29
12/07/19
19:29
Hot Stocks
Bristol-Myers Squibb-Pfizer Alliance reports analysis of Eliquis »

The Bristol-Myers…

PFE

Pfizer

$38.29

0.26 (0.68%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

UMRX

Unum Therapeutics

$0.70

0.0177 (2.61%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Hot Stocks
Unum Therapeutics announces Phase 1 clinical updates for T-cell therapies »

Unum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

19:23
12/07/19
12/07
19:23
12/07/19
19:23
Hot Stocks
Autolus presents new data on T cell therapies in leukemia, lymphoma »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:19
12/07/19
12/07
19:19
12/07/19
19:19
Hot Stocks
Bristol-Myers says lisocabtagene maraleucel study met both endpoints »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

SGEN

Seattle Genetics

$117.52

0.37 (0.32%)

19:16
12/07/19
12/07
19:16
12/07/19
19:16
Hot Stocks
Seattle Genetics reports updated Adcetris plus Opdivo Hodgkin lymphoma data »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 15

    Mar

GILD

Gilead

$67.09

1.16 (1.76%)

19:12
12/07/19
12/07
19:12
12/07/19
19:12
Hot Stocks
Gilead's Kite announces long-term data from ZUMA-1 study in lymphoma »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CRTX

Cortexyme

$28.00

-6.15 (-18.01%)

19:10
12/07/19
12/07
19:10
12/07/19
19:10
Hot Stocks
Cortexyme says COR388 reduced levels of ApoE protein in Phase I study »

Cortexyme announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$3.40

0.015 (0.44%)

12:15
12/07/19
12/07
12:15
12/07/19
12:15
Hot Stocks
Mallinckrodt presents data on infantile spasms predictive model »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

12:13
12/07/19
12/07
12:13
12/07/19
12:13
Hot Stocks
Stoke Therapeutics presents preclinical data from studies of STK-001 »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTO

Aptose Biosciences

$2.55

-0.04 (-1.54%)

12:11
12/07/19
12/07
12:11
12/07/19
12:11
Hot Stocks
Aptose reports CG-806 data in patients with chronic lymphocytic leukemia »

Aptose Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

SGMO

Sangamo

$11.65

0.05 (0.43%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

09:14
12/07/19
12/07
09:14
12/07/19
09:14
Hot Stocks
Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study »

Sangamo Therapeutics…

SGMO

Sangamo

$11.65

0.05 (0.43%)

PFE

Pfizer

$38.29

0.26 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.